Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1558

Sort by

Sort Order Select

Journal Articles

Mouse multipotent progenitor 5 cells are located at the interphase between hematopoietic stem and progenitor cells

Pia Sommerkamp, Mari Carmen Romero-Mulero, Andreas Narr, Luisa Ladel, Lucie Hustin, Katharina Schönberger, Simon Renders, Sandro Altamura, Petra Zeisberger, Karin Jäcklein, Daniel Klimmeck, Alejo Rodriguez-Fraticelli, Fernando D. Camargo, Leïla Perié, Andreas Trumpp, Nina Cabezas-Wallscheid

Blood (2021) 137 (23): 3218–3224.

https://doi.org/10.1182/blood.2020007876

Published: 2021

Includes: Supplemental data

Journal Articles

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

Blood (2021) 137 (22): 3093–3104.

https://doi.org/10.1182/blood.2020007626

Published: 2021

Includes: Supplemental data

Journal Articles

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

Semjon Willier, Paula Rothämel, Maximilian Hastreiter, Jonas Wilhelm, Dana Stenger, Franziska Blaeschke, Meino Rohlfs, Theresa Kaeuferle, Irene Schmid, Michael H. Albert, Vera Binder, Marion Subklewe, Christoph Klein, Tobias Feuchtinger

Blood (2021) 137 (8): 1037–1049.

https://doi.org/10.1182/blood.2020006921

Published: 2021

Includes: Supplemental data

Journal Articles

How I diagnose and treat NPM1 -mutated AML

Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli

Blood (2021) 137 (5): 589–599.

https://doi.org/10.1182/blood.2020008211

Published: 2021

Journal Articles

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Michael Pepper, Brent Tan

Blood (2020) 136 (12): 1467.

https://doi.org/10.1182/blood.2020007198

Published: 2020

Journal Articles

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia

Melat T. Gebru, Jennifer M. Atkinson, Megan M. Young, Lijun Zhang, Zhenyuan Tang, Zhenqiu Liu, Pinyi Lu, Christopher M. Dower, Longgui Chen, Charyguly Annageldiyev, Arati Sharma, Yuka Imamura Kawasawa, Zhongming Zhao, Barbara A. Miller, David F. Claxton, Hong-Gang Wang

Blood (2020) 136 (9): 1067–1079.

https://doi.org/10.1182/blood.2019003124

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat relapsed or refractory AML

Susan DeWolf, Martin S. Tallman

Blood (2020) 136 (9): 1023–1032.

https://doi.org/10.1182/blood.2019001982

Published: 2020

Journal Articles

Deletions in BCP-ALL result in a TAD more FLT3

David H. Spencer

Blood (2020) 136 (8): 919–920.

https://doi.org/10.1182/blood.2020006607

Published: 2020

Journal Articles

13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking

Minjun Yang, Setareh Safavi, Eleanor L. Woodward, Nicolas Duployez, Linda Olsson-Arvidsson, Jonas Ungerbäck, Mikael Sigvardsson, Marketa Zaliova, Jan Zuna, Thoas Fioretos, Bertil Johansson, Karolin H. Nord, Kajsa Paulsson

Blood (2020) 136 (8): 946–956.

https://doi.org/10.1182/blood.2019004684

Published: 2020

Includes: Supplemental data

Journal Articles

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Blood (2020) 135 (17): 1472–1483.

https://doi.org/10.1182/blood.2019003538

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Blood (2020) 135 (5): 371–380.

https://doi.org/10.1182/blood.2019002697

Published: 2020

Includes: Supplemental data

Journal Articles

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo, Andrew H. Wei

Blood (2020) 135 (2): 85–96.

https://doi.org/10.1182/blood.2019001239

Published: 2020

Includes: Supplemental data

Journal Articles

Terminal deoxynucleotidyl transferase promotes acute myeloid leukemia by priming FLT3 -ITD replication slippage

Julian Borrow, Sara A. Dyer, Susanna Akiki, Michael J. Griffiths

Blood (2019) 134 (25): 2281–2290.

https://doi.org/10.1182/blood.2019001238

Published: 2019

Includes: Supplemental data

Journal Articles

Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT

Julian Borrow, Sara A. Dyer, Susanna Akiki, Michael J. Griffiths

Blood (2019) 134 (25): 2291–2303.

https://doi.org/10.1182/blood.2019001240

Published: 2019

Includes: Supplemental data

Journal Articles

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Rhonda E. Ries, MA, Amanda R. Leonti, MS, Timothy Junius Triche, Jr., PhD, Robert B. Gerbing, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Jenny L. Smith, MSc, MD, Todd M Cooper, DO, Jason E. Farrar, MD, Aniruddha J. Deshpande, E. Anders Kolb, MD, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 461.

https://doi.org/10.1182/blood-2019-125943

Published: 2019

Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip

Blood (2019) 134 (Supplement_1): 546.

https://doi.org/10.1182/blood-2019-128373

Published: 2019

Journal Articles

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Kensuke Sasaki, MD, Kohta Miyawaki, MD PhD, Yuichiro Semba, MD PhD, Koji Kato, MD PhD, Jumpei Nogami, PhD, Takeshi Sugio, MD PhD, Toshihiro Miyamoto, MD PhD, Yoshikiyo Ito, MD PhD, Koji Nagafuji, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 375.

https://doi.org/10.1182/blood-2019-129625

Published: 2019

Journal Articles

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Marc Botteman, MS, MA, Ruchit Shah, PhD, Linlin Luo, MSc, Zhenming Shun, PhD, Saurabh Ray, PhD

Blood (2019) 134 (Supplement_1): 382.

https://doi.org/10.1182/blood-2019-123554

Published: 2019

Journal Articles

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Konstantinos Tzelepis, Aristi Damaskou, MSc, Vijay Baskar, PhD, Penny Wright, Graham Duddy, Eshwar Meduri, PhD, Milena Mazan, PhD, Kosuke Yusa, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath, George S. Vassiliou, FRCPath, MRCP, PhD

Blood (2019) 134 (Supplement_1): 111.

https://doi.org/10.1182/blood-2019-126505

Published: 2019

NARROW

Mouse multipotent progenitor 5 cells are located at the interphase between hematopoietic stem and progenitor cells

Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin

CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy

How I diagnose and treat NPM1 -mutated AML

Acute myeloid leukemia with NPM1 and FLT3 ITD mimicking acute promyelocytic leukemia

Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia

How I treat relapsed or refractory AML

Deletions in BCP-ALL result in a TAD more FLT3

13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD + acute myeloid leukemia

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

How I treat acute myeloid leukemia in the era of new drugs

Terminal deoxynucleotidyl transferase promotes acute myeloid leukemia by priming FLT3 -ITD replication slippage

Molecular roulette: nucleophosmin mutations in AML are orchestrated through N-nucleotide addition by TdT

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only